Hubei Jumpcan Pharmaceutical (600566) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 1.21 billion, down 20.84% year-over-year.

• Net profit attributable to shareholders was RMB 400.14 million, a 9.13% decrease year-over-year.

• Operating cash flow increased 10.89% year-over-year to RMB 880.34 million.

Financial highlights

• Total assets at quarter-end were RMB 17.84 billion, up 0.77% from year-end 2025.

• Shareholders’ equity rose 2.62% to RMB 14.99 billion compared to year-end 2025.

• Basic and diluted EPS were both RMB 0.44, down 8.33% year-over-year.

• Gross margin for Q1 2026 was 30.97%, compared to 27.34% in Q1 2025.

Key financial ratios and metrics

• Weighted average ROE was 2.7%, down 0.25 percentage points year-over-year.

• Net cash from operating activities was RMB 880.34 million, up from RMB 793.90 million in Q1 2025.

• Net cash used in investing activities was RMB -2.55 billion, compared to RMB -9.20 million in Q1 2025.

• Net cash from financing activities was RMB 160.13 million, up from RMB -38.95 million in Q1 2025.